<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:AERI (USA) Also Trade In: Germany

Aerie Pharmaceuticals Inc $ 20.51 -0.74 (-3.48%)

Volume:
1,616,087
Avg Vol (1m):
1,269,766
Market Cap $:
942.21 Mil
Enterprise Value $:
851.60 Mil
P/E (TTM):
0.00
P/B:
5.93
Warning! GuruFocus has detected 4 Severe warning signs with AERI. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for AERI (Aerie Pharmaceuticals) from 2013 to Oct 19 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Aerie Pharmaceuticals stock (AERI) PE ratio as of Oct 19 2019 is 0. More Details

Aerie Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Aerie Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1251
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Aerie Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-190.0 2019-08-190.0
2019-10-180.0 2019-08-160.0
2019-10-170.0 2019-08-150.0
2019-10-160.0 2019-08-140.0
2019-10-150.0 2019-08-130.0
2019-10-140.0 2019-08-120.0
2019-10-110.0 2019-08-090.0
2019-10-100.0 2019-08-080.0
2019-10-090.0 2019-08-070.0
2019-10-080.0 2019-08-060.0
2019-10-070.0 2019-08-050.0
2019-10-040.0 2019-08-020.0
2019-10-030.0 2019-08-010.0
2019-10-020.0 2019-07-310.0
2019-10-010.0 2019-07-300.0
2019-09-300.0 2019-07-290.0
2019-09-270.0 2019-07-260.0
2019-09-260.0 2019-07-250.0
2019-09-250.0 2019-07-240.0
2019-09-240.0 2019-07-230.0
2019-09-230.0 2019-07-220.0
2019-09-200.0 2019-07-190.0
2019-09-190.0 2019-07-180.0
2019-09-180.0 2019-07-170.0
2019-09-170.0 2019-07-160.0
2019-09-160.0 2019-07-150.0
2019-09-130.0 2019-07-120.0
2019-09-120.0 2019-07-110.0
2019-09-110.0 2019-07-100.0
2019-09-100.0 2019-07-090.0
2019-09-090.0 2019-07-080.0
2019-09-060.0 2019-07-050.0
2019-09-050.0 2019-07-040.0
2019-09-040.0 2019-07-030.0
2019-09-030.0 2019-07-020.0
2019-09-020.0 2019-07-010.0
2019-08-300.0 2019-06-280.0
2019-08-290.0 2019-06-270.0
2019-08-280.0 2019-06-260.0
2019-08-270.0 2019-06-250.0
2019-08-260.0 2019-06-240.0
2019-08-230.0 2019-06-210.0
2019-08-220.0 2019-06-200.0
2019-08-210.0 2019-06-190.0
2019-08-200.0 2019-06-180.0

Aerie Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Drug Manufacturers » Drug Manufacturers NAICS : 325412 NAICS : 2836
Traded in other countries 0P0.Germany AERI.USA
Address 4301 Emperor Boulevard, Suite 400, Durham, NC, USA, 27703
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.